Clinical Team: Chiara Elena, Elisa Bono, Jacqueline Ferrari, Elisa Rumi, Ilaria C. Casetti, Oscar Borsani, Nicolas Fiorelli, Virginia Camilotto, Martina Boldini;
Laboratory Team: Anna Gallì, Elisabetta Molteni, Sara Pozzi, Daniela Pietra, Silvia Catricalà, Cristina Picone, Marina Boni, Irene D’Ambruoso, Rita Zappatore.
RESEARCH PROJECTS
Clinical and translational research activity is focused on (i) understanding of the molecular basis of hematologic malignancies; (ii) development, transfer and implementation of precision medicine approaches; (iii) molecular and clinical characterization of pre-malignant states.
Multi-omics and single-cell analysis are applied to characterize malignant clones, clonal hierarchies and pathways of clonal progression. The role of Microenvironment in promoting selective clonal expansion is investigated through single-cell RNA sequencing, and 3D scaffold culture models.
The evolutionary trajectories of malignant clones are analyzed via Patient-derived models (iPSCs) and CRISPR/Cas9-based genome editing to identify actionable vulnerabilities and to develop platforms for drug screening. Novel therapeutic targets are screened as a basis for Drug development and innovative clinical trials, including cell- and antibody-mediated immunotherapy, and inhibition through small molecules.
Highly-sensitive, patient-specific minimal residual disease monitoring protocols are developed to guide early and pre-emptive therapeutic intervention with immunotherapy approaches.
5 BEST PAPERS
RUNNING FUNDS
NATIONAL AND INTERNATIONAL STRATEGIC COLLABORATIONS